Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study

We provide a comparison of the bullous pemphigoid (BP)-free survival probability in patients starting PD-1/PD-L1 inhibitors and DPP-4 inhibitors that has not been previously demonstrated in other studies. A propensity-matched retrospective cohort study performed with TriNetX participants revealed a significantly increased risk of BP in patients starting PD-1/PD-L1 inhibitors, especially in male patients and those aged > 65 years.